GENERAL30 Sept 2026
Jefferies's top stock recommendation: Buy rating with 27% upside | Indian share up 57% against IPO price in one month | Stock Market News
Jefferies has begun covering Molbio Diagnostics with a 'buy' rating and a ₹1,600 target price. Molbio's newly listed shares closed at ₹1,272, up 57% from its ₹807 initial public offering price. The brokerage expects 22% yearly revenue growth and a 47% profit growth by FY29, led by its Truenat testing platform. Treat these as analyst views, not guarantees.
Key Statutory Highlights
- Molbio Diagnostics shares closed at ₹1,272 on the NSE, up over 57% against its IPO price of ₹807.
- Jefferies initiated coverage with a 'buy' rating and a price target of ₹1,600.
- Jefferies expects Molbio to deliver 22% revenue CAGR and a 47% PAT CAGR from FY26 to FY29E, helped by Truenat, Prorad and Optrascan.
Actionable Advice for Taxpayers / Founders:If you are thinking of investing in Molbio Diagnostics, check your own risk appetite and speak to a certified financial expert first. A brokerage rating is one view, not a promise of returns.
Statutory Disclaimer: TaxQue Shorts are AI-assisted editorial briefs for compliance awareness. This brief has not passed every source check; confirm the original notification before acting. This does not constitute formal legal or CA counsel.
TaxQue News Desk
Share: